10-Q: Drugs Made in America Acquisition II Corp. Q1 2026 Update

Drugs Made in America Acquisition II Corp. reports Q1 2026 results, with net income driven by trust account interest, while continuing search for a business combination.

Summary

• The company reported a net income of $4,337,820 for the first quarter of 2026, a significant increase from a net loss of $59,327 in the same period of 2025.
• This income was primarily driven by $4,439,850 in interest earned on cash and investments held in the Trust Account, along with a $30,000 recovery of credit losses.
• Operating expenses, specifically general and administrative costs, were $132,030 for Q1 2026, up from $59,327 in Q1 2025.
• As of March 31, 2026, the company held $509,725,411 in total assets, with $509,373,650 in cash and investments held in the Trust Account.
• Total liabilities were $18,166,285 as of March 31, 2026, primarily consisting of a $17,500,000 deferred underwriting fee.
• The company continues its search for a business combination target, with a 24-month period from the IPO closing (September 26, 2025) to complete a business combination.
• A reserve for expected credit losses of $782,113 was established for the amount due from the Sponsor, as repayment is considered unlikely.
• The company has identified material weaknesses in its internal controls, including inadequate segregation of duties, insufficient written policies, and a lack of formal review for related party transactions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the ongoing search for a business combination, the identified material weaknesses in internal controls, and the substantial doubt about going concern, despite the positive net income driven by trust account interest.

Positives

• Reported a net income of $4,337,820 for Q1 2026, a substantial improvement from a net loss in the prior year period.
• Significant interest income of $4,439,850 was generated from the Trust Account.
• Successfully managed to recover $30,000 in credit losses.
• The company has a substantial amount of funds in its Trust Account ($509,373,650 as of March 31, 2026) available for a business combination.
• The company has entered into new agreements for consulting and CEO compensation, indicating progress in operational structuring.

Negatives

• The company has a working capital deficit of $314,524 as of March 31, 2026.
• A full reserve of $782,113 has been established for the amount due from the Sponsor due to unlikely repayment.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's business plan is dependent on completing a business combination within a specific timeframe, raising going concern doubts.
• Deferred underwriting fees of $17,500,000 are a significant liability that becomes payable only upon a successful business combination.

Risks

• The company must complete a business combination within 24 months of the IPO closing (September 26, 2025), or it will cease operations and liquidate.
• There is substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued.
• The company is subject to risks associated with early-stage and emerging growth companies.
• Geopolitical events, such as the conflicts in Ukraine and the Middle East, could adversely affect the company's ability to complete a business combination.
• The company relies on third-party digital technologies and is vulnerable to cybersecurity threats, with limited internal resources to mitigate these risks.
• The company has identified material weaknesses in its internal controls, which could lead to errors or fraud.

Future Outlook

The company's primary objective is to complete an initial business combination within the 24-month Combination Period. Its business plan is entirely dependent on this, and failure to do so will result in the cessation of operations and liquidation. The company expects to incur significant costs in pursuit of this goal.

Management Comments

• Management has determined that conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.
• Management believes that the probability of repayment of the amount due from the Sponsor is remote.
• Management has concluded that the Company's disclosure controls and procedures were not effective due to material weaknesses.
• Management does not believe that any other recently issued, but not yet effective, accounting standards would have a material effect on the Company's financial statements.

Industry Context

StockSavvy.ai notes that as a Special Purpose Acquisition Company (SPAC), Drugs Made in America Acquisition II Corp. operates in a unique segment of the market focused on identifying and merging with private companies. The current environment for SPACs involves increased scrutiny and a need for robust due diligence to ensure successful business combinations, especially given the stated intention to focus on the pharmaceutical industry.

Comparison to Industry Standards

• As a SPAC, direct comparison to operating companies is not applicable. Its financial performance is largely driven by interest income from its trust account, which is standard for SPACs.
• The company's net income of $4.3 million for the quarter is primarily from interest income, which is typical for SPACs holding significant capital in trust accounts.
• The identification of material weaknesses in internal controls is a concern, though not uncommon for early-stage companies or SPACs with limited personnel during their formation and IPO phases. However, addressing these is critical for investor confidence.
• The company's timeline to complete a business combination (24 months) is a standard benchmark for SPACs.

Management Changes

Corporate Governance

Legal Proceedings

• To the knowledge of management, there is no litigation currently pending against the company, its officers, or directors in their capacity as such, or against any of its property.

Related Party Transactions

• The Sponsor withdrew $1,345,844 from the company's working capital account, of which $325,000 repaid a note and $208,731 repaid offering costs, leaving an outstanding balance of $812,113 due back to the company, which has been fully reserved for due to unlikely repayment.
• An Administrative Services Agreement with the Sponsor or an affiliate for $10,000 per month was cancelled in March 2026. $30,000 incurred under this agreement was reclassified as a capital contribution.
• A Consulting Agreement with Titan Advisory Services LLC (for CFO services by Saleem Elmasri) incurred $10,500 in Q1 2026. Mr. Elmasri is also entitled to receive 175,000 ordinary shares upon execution of a definitive agreement.
• A CEO Compensation Agreement with Aleutian Equity Holdings LLC (affiliate of Roger E. Bendelac) provides for $4,500 per month compensation (partially deferred) and 250,000 ordinary shares upon execution of a definitive agreement.
• The Sponsor previously issued a promissory note for up to $325,000, which was repaid by the company on September 29, 2025.

Stakeholder Impact

• Shareholders: The company's primary goal is to complete a business combination, which is crucial for shareholder value. Failure to do so within the timeframe will result in liquidation, returning the per-share amount from the trust account.
• Sponsor: The Sponsor has significant founder shares and private placement units, and its ability to recoup its investment and generate profit is tied to a successful business combination. The reserve for credit losses against the amount due from the Sponsor indicates a potential financial strain on the Sponsor.
• Creditors: The company has minimal current liabilities, but potential claims from creditors could impact the trust account if not adequately waived.
• Employees: The company has appointed a new CFO and CEO, with compensation agreements that include share grants, indicating a focus on building the management team for future operations.

Next Steps

• Continue to identify and pursue a suitable business combination target.
• Complete a business combination within the 24-month Combination Period.
• Address the material weaknesses in internal controls.
• Manage ongoing operational and professional costs.
• Potentially engage in further financing activities if required.

Key Dates

Recommendation

The company is a SPAC with no operating business yet. While it has substantial capital in its trust account, the significant risk of failing to complete a business combination within the allotted time, coupled with identified material weaknesses in internal controls and going concern doubts, warrants a 'hold' recommendation. Investors should await clarity on a definitive business combination target and resolution of control deficiencies.

Keywords

Special Purpose Acquisition Company, SPAC, Business Combination, Trust Account, Quarterly Report, SEC Filing, Financial Statements, Emerging Growth Company, Pharmaceutical Industry, Drugs Made in America Acquisition II Corp.